<DOC>
	<DOCNO>NCT03056989</DOCNO>
	<brief_summary>Ascending dose , 7-day , open label safety trial SPX-101 Inhalation Solution adult subject cystic fibrosis .</brief_summary>
	<brief_title>A Safety Study SPX-101 Inhalation Solution Subjects With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Confirmed diagnosis CF FEV1 â‰¥ 40 % predict normal Stable CF lung disease Nonpregnant , nonlactating female Significant unstable comorbidities within 28 day screen judged Investigator . Has receive investigational drug within past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>